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Summary. Historically, platelet transfusion has proven a
reliable way to treat patients suffering from thrombocyto-
penia or similar ailments. An undersupply of donors,
however, has demanded alternative platelet sources. Sci-
entists have therefore sought to recapitulate the biological
events that convert hematopoietic stem cells into platelets
in the laboratory. Such platelets have shown good func-
tion and potential for treatment. Yet the number manu-
factured ex vivo falls well short of clinical application.
Part of the reason is the remarkable gaps in our under-
standing of the molecular mechanisms driving platelet
formation. Using several stem cell sources, scientists have
progressively clarified the chemical signaling and physical
microenvironment that optimize ex vivo platelets and
reconstituted them in synthetic environments. Key
advances in cell reprogramming and the ability to propa-
gate self-renewal have extended the lifetime of megak-
aryocytes to increase the pool of platelet progenitors.
Keywords: bioreactors; blood platelets; induced
pluripotent stem cells; megakaryocytes; polyploidy.
Introduction
Platelets are best known for their role in wound repair,
but have responsibility in several other functions, includ-
ing innate immunity, vascular integrity, and neoangiogen-
esis. The human body has several hundred billion
circulating platelets at any one time and recycles its entire
platelet population every 10 days [1]. Because of its long
history and success, platelet transfusion has remained the
most popular way to provide platelets to patients suffer-
ing from thrombocytopenia and other ailments that
require an external platelet source. However, because
platelets must be preserved at room temperature, they
risk bacterial contamination, which gives them a shelf life
of only a few days. Thus, donors are continuously being
sought to replenish a fragile supply that often sees unac-
ceptable proportions go to waste [2]. Improved life spans
and medical technologies have only intensified this
demand at a rate which platelet donors have not kept up.
Indeed, in some nations, it has been estimated that the
donor population will underserve by 20% [3]. Thus, alter-
native sources for platelets have received attention, espe-
cially those that generate platelets ex vivo.
One example is hematopoietic stem cells (HSCs), which
can be differentiated to megakaryocytes (MKs), the unipo-
tent progenitor of all platelets, and acquired from umbili-
cal cord blood (UCB). A typical platelet unit for
transfusion will contain in the neighborhood of 500 billion
platelets, and the average MK in the body produces 2000–
5000 platelets, but a typical UCB unit only 1 million HSCs
[4]. Therefore, assuming 1000 platelets can be gathered
from a single MK in the laboratory, HSCs will have to be
expanded at least 100 times. However, current ex vivo
techniques generate fewer than 100 platelets per MK,
meaning the expansion will have to be even greater [5].
To achieve these numbers, scientists have comprehen-
sively investigated the chemical signaling and physical
microenvironment that promote MK differentiation, mat-
uration, and the release of platelets into the blood stream.
Accordingly, a number of groups have designed bioreac-
tors that recapitulate the microenvironment to promote
these events. Complementing this strategy are cell repro-
gramming methods that take advantage of the limitless
proliferation of stem cells to generate self-renewing MKs.
In this review, we examine the biological steps considered
essential to platelet generation and give attention to meth-
ods that promise to acquire sufficient ex vivo platelets for
clinical application.
From megakaryocyte to platelet
Megakaryocytes
Platelets are the anucleated fragments of MKs. In the
most accepted hierarchical model, HSCs, or CD34+ cells,
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take the MK lineage through a number of intermediates,
with MK-erythroid precursor (MEP) being the penulti-
mate stage [6]. Upon maturation, MKs extend proplat-
elets, which traverse into the sinusoidal vessels of the
bone marrow where they are shred by blood flow into
platelets [7]. By this point, the cells will have switched
their distinctive markings from CD34+ to
CD41a+CD42b+. Strategies for platelet generation
ex vivo use this model as the paradigm. Yet as a testa-
ment on how much there is still to learn about thrombo-
poiesis, two recent studies have found that HSCs show
surface markings that bias their fate to the MK lineage
well before the MEP stage [8,9].
During the differentiation process, a HSC will enter the
osteoblast niche and migrate to the perivascular niche to
achieve full differentiation. Three transcription factors,
GATA1, RUNX1, and NF-E2, are considered the pri-
mary determinants of whether MEP will take the MK
lineage and proceed with this migration [10]. Thrombo-
poietin (TPO) is the primary cytokine responsible for the
differentiation and binds to c-MPL receptors on CD34+
cells to lead them to the osteoblast niche [11]. The discov-
ery of TPO is considered a cornerstone to our under-
standing of platelet generation. Indeed, a year after this
discovery, the first report to describe in vitro platelet gen-
eration was published [12]. The elimination of either TPO
or c-MPL receptors results in severe thrombocytopenia
and reduces the number of MK progenitors and mature
MKs [13]. Once in the osteoblast niche, CD34+ cells
interact with collagen I via GPVI and a2b1 [14]. The sta-
bility of this niche depends on the protein-tyrosine phos-
phatases Shp1 and Shp2, which regulate the expression of
GPVI and Mpl, respectively [15]. In addition to TPO,
several studies have demonstrated that a minimal concoc-
tion for CD34+ expansion includes stem cell factor (SCF)
and at least one other cytokine [5]. Notch signaling via
activation by the Delta-1 ligand has been reported to
increase expansion 100 times in vitro, and Stem Regenin
1, a purine derivative, has been found to have a signifi-
cant positive effect on human CD34+ cells by blocking
aryl hydrocarbon receptors [16,17]. More recent studies
have found small molecules can have positive effects on
CD34+ cell expansion using other mechanisms of action
[18,19].
The maturation of MKs is marked by a massive
increase in size, as these cells can reach up to 100 lm in
diameter. The reason for the large size is that MKs switch
from mitosis to endomitosis due to a failure in cytokine-
sis, which is due to an abnormal contractile ring caused
by the absence of myosin II and regulation by RUNX1
[20,21]. While endomitosis explains how fully mature
MKs can reach DNA content up to 128N, MKs have
been observed to mature using either mitosis or endomi-
tosis, which would explain the variable ploidy in blood
and why less ploidy is sufficient for shedding platelets
[22]. This increase in size leads to the invaginated mem-
brane system (IMS), which acts as a membrane reservoir
for proplatelets. Proplatelets enter the sinusoidal vessels
of the bone marrow and are shred into platelets by blood
flow at the very last stage of thrombopoiesis. Polyploidy
is thought important for MKs to accumulate the cyto-
plasmic content that will eventually be used for platelet
formation. Indeed, it has been argued that ploidy level
correlates directly with the number of platelets [23].
Exceptions to this claim are known, however [24,25].
The regulation of the mitosis–endomitosis transition
appears to involve multiple mechanisms. Gao et al. [26]
showed that GEF-H1 and ECT2 must be downregulated
for endomitosis, but that their downregulation occurs
sequentially: GEF-H1 occurs in the 2N–4N transition,
whereas ECT2 occurs thereafter. Whether these molecules
make useful targets for increasing the ploidy of MKs in
ex vivo platelets generation has not been explored.
As endomitosis proceeds, so too does the size of the
IMS, which will eventually disperse throughout the MK.
The forces required for the invaginations are initiated by
phosphatidylinositol 4,5-bisphosphate, which activates the
WASP–WAVE pathway, which in turn promotes actin
assembly [27,28]. Interestingly, despite the ubiquity of the
IMS in MKs, its beginnings are localized at one region of
the surface membrane, which is marked by GPIb recep-
tors [29]. Not coincidently, GPIb receptors are also mark-
ers for MK maturation and the transition to the
perivascular niche by the cytokine SDF1 and its receptor
CXCR4, which have been observed to accelerate the poly-
ploidization of MKs [30,31]. The perivascular niche is
made up of several extracellular matrix proteins including
von Willebrand factor (vWF), fibrinogen, and fibronectin
and is where MKs will begin to extend proplatelets using
the organelles and granules accumulated by endomitosis.
GPIb-IX-V is the receptor for vWF, a glycoprotein that
facilitates platelet adhesion to the subendothelium. vWF
appears to have an important role at the very end stages
of platelet generation, as its absence has been associated
with fewer platelets being shed from MKs [32,33]. Fibrin-
ogen binds to aIIbb3 upon MK maturation and can be
used to promote proplatelets [34,35]. Finally, fibronectin
promotes proplatelet formation by binding to the recep-
tors VLA-4 and VLA-5 [36].
Proplatelets
Visually, proplatelets have numerous swellings that give
them the shape of a chain of dumbbells, with each swell-
ing containing the components necessary for a functional
platelet. Once in the bloodstream, the proplatelet will be
eviscerated at the center of these dumbbells, resulting in
two approximately symmetric daughters that can continue
to be eviscerated until platelet-sized entities emerge [37].
A single MK will continue to extend proplatelets until
finally no more of its cell body remains and its remnants
are degraded. It has even been observed that platelets them-
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selves extend protrusions that can be further shed into
structures that show surface markings indicative of nor-
mal platelets [38]. How the system knows when to end
this reductionism is not clear.
Proplatelets are dynamic structures continuously
changing their shape [37]. Cytoskeletal proteins are con-
stantly transporting organelles and granules bidirection-
ally to the proplatelets, which are regularly branching
to extend more surface area that will increase the num-
ber of platelets [39,40]. However, these dynamics are
nothing but inefficient if they do not guide the proplat-
elet to the sinusoidal blood vessels. Using mutant mice,
Zhang et al. [41] showed the important role of sphingo-
sine 1 phosphate (S1P) and its receptor, S1pr1, on pro-
platelet formation and platelet shedding. Knockdown of
S1pr1 led to a significant decrease in platelet count.
Furthermore, the mechanisms leading to the last stages
of platelet formation appeared unperturbed, as the num-
ber of MKs was unchanged, the establishment of the
IMS was normal, and MKs retained their strong prox-
imity to the sinusoidal vessels. Rather, what did appear
disrupted was the proplatelet preference for the vessels,
as the proplatelets protruded in random directions sug-
gesting insensitivity to the S1P gradient between the
lumen and blood.
Even if proplatelets are lured to the endothelial wall by
the S1P gradient, they must still find a way to penetrate
and enter the blood stream. Schachtner et al. [42] found
that podosomes on the MK surface can degrade the
extracellular matrix, which may provide the gateway for
proplatelets to enter the vessels. Podosome activation
depends on WASP signaling, as podosomes are actin-rich
structures, which is consistent with the degradation being
reduced by blebbistatin, a myosin II inhibitor. Interest-
ingly, blebbistatin has been shown to promote platelet
generation ex vivo [43,44].
Generating platelets in the laboratory
Immortalized MKs
Using the knowledge gained about the differentiation of
MKs and the shedding of platelets, scientists have sought
to induce CD34+ cells to the MK lineage. CD34+ cells
can be acquired from several sources, including bone
marrow, peripheral blood, or UCB. MKs from UCB are
generally smaller in size and ploidy [45]. In addition, they
shed significantly fewer platelets and show distinctive
characteristics from MKs in adult blood [23,46]. Human
embryonic stem cells (hESCs) and human induced plurip-
otent stem cells (hiPSCs) are immortal and in theory can
provide a limitless number of CD34+ cells. Bluteau et al.
[47] showed by global transcriptome analysis the tran-
scription factor network and signaling pathways of
megakaryopoiesis in hESCs are more similar to those in
HSCs from neonatal blood than those from adult blood,
suggesting studies using UCB can be extrapolated to
hESCs and hiPSCs.
Gaur et al. [48] were the first to show how human
hESCs can be differentiated into MKs by culturing them
with OP-9 stromal cells. However, these MKs did not
exceed a ploidy of 32N and the number generated per
starting hESC was less than one. Lu et al. [49] were able
to generate functional platelets that bound to fibrinogen
and vWF starting with hESCs cultured in TPO, SCF, and
IL-11. Several hESC lines were expanded approximately
100-fold into MKs, but only 15% of these MKs were
CD41a+CD42b+. Vascular endothelial growth factor
(VEGF) may be another molecule that facilitates expan-
sion, as it was found to generate sac-like structures that
seemed to harbor environments more suitable for obtain-
ing a number of hematopoietic progenitors, including
MK progenitors, and also maturing MKs that shed func-
tional platelets [50]. Here too, however, the number of
platelets is untenable for clinical purposes. Additionally,
the platelets observed in these ex vivo studies were larger
and more heterogeneous in size than those found in
blood. One possible explanation is that the ex vivo gener-
ation was carried out in static culture, which did not
mimic blood flow eviscerating proplatelets to proper size.
Because they appear to function equivalently, hiPSCs
offer a preferred option to hESCs for several reasons,
including the absence of ethical controversies and the
ability to make any somatic cell in the body a potential
source for MKs. One of the more important develop-
ments in thrombopoiesis using hiPSCs has been the
reporting of immortalized MKs. These cells possess
unlimited replication potential while still retaining unipo-
tency, which mitigates the concern of contaminating cells.
Nakamura et al. [51] have reported a way to extend the
lifetime of hiPSC-derived MKs from 2 months to
5 months, a period that could potentially compensate for
the low number of platelets shed by MKs ex vivo. Key to
this accomplishment was the manipulation of c-Myc, a
transcription factor stimulated by TPO and one of the
four Yamanaka factors used to induce pluripotency in
somatic cells [52,53]. Overexpression of c-Myc has been
found to increase the proliferation of MKs in mice, but
at the cost of decreased maturation and polyploidy [54].
Taking advantage of the aforementioned sac-like struc-
tures, Takayama et al. [55] found that c-Myc expression
was accompanied by an increase in the expressions of p14
(ARF) and p16 (INK4A). Like c-Myc, the activation of
these two apoptotic factors has been associated with an
inability of MKs to mature and increase their ploidy, per-
haps explaining the dysfunctional platelets seen by Na-
kamura et al. and the need to control the expression of
these three factors temporally [56,57]. To resolve this
problem, Nakamura et al. used a destabilization domain
vector system to more precisely regulate c-Myc expression
and incorporated BMI1, a polycomb complex component,
to do the same with ARF and INK4A expression [58,59].
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However, even then, MKs showed aberrant properties
including normal CD41a+ levels but reduced CD42b+
levels due to the activation of caspases. This problem was
resolved by adding BCL-XL [60], an anti-apoptosis agent
that has been associated with platelet shedding, to the
culture. Important was to add BCL-XL sequentially, two
to three weeks after introducing c-Myc and BMI1, as
mixing all simultaneously had no beneficial effect. The
reduced expression of these factors was accompanied by
an increase in the expressions of GATA1 and NF-E2.
That c-Myc and other factors must be controlled in a rel-
atively small time window suggests the signaling program
for platelet generation is an ongoing dynamic process that
can be easily perturbed. As an example of this sensitivity,
another study has shown that c-Myc and BCL-XL can be
used to tip MEP to erythrocyte lineage [61].
However, like others before it, immortalized MKs do
not provide the requisite number of platelets, as each only
sheds approximately 3–10 platelets [51]. Moreover, the
platelets showed less robust response than fresh human
platelets in vitro, even though they had all the surface
receptor markings of proper function and responded to
injury in a mouse model. One possible explanation is the
lower ploidy of these MKs. Thus, one strategy could be
culturing methods that increase the ploidy number and
cell size by aggressive maturation. A very simple way to
do this is culturing the cells with nicotinamide [62,63],
although such treatment has controversial effects on pro-
platelet robustness and platelet function [64,65]. If
increasing the size and ploidy of MKs does increase the
number functional platelets, an ex vivo strategy for this
purpose will likely require the identification of a new
factor.
Nevertheless, a unique appeal of immortalized MKs is
that they can be cryopreserved, which means they can be
stored a much longer period than other derived MKs.
This feature could mitigate the low platelet yield per MK,
as it might be possible to store and access a larger num-
ber of MKs when required. This feature would have even
more impact as the number of platelets generated per sin-
gle immortalized MK is increased (Fig. 1).
One caveat to cell reprogramming is the risk of tumors
due to the viral transduction of the transcription factors.
Platelets, being anucleate, can be irradiated to kill off any
contaminating cells. However, it is still preferred to mini-
mize this potential in every step of the differentiation pro-
tocol, which is why alternative reprogramming methods,
such as transduction by small molecules are being
explored [66]. Feng et al. [43] reported that the small mol-
ecule iBET151 could be used to inhibit c-Myc expression
and still managed to generate immortalized MKs that
shed functional platelets. Furthermore, they could
improve the yield of CD41a+CD42b+ cells by mild
hyperthermia, which has been observed to increase MK
differentiation [67]. In addition, they were able to increase
the percentage of CD41a+CD42b+ MKs by adding
GM6001 or MMP8-I to the culture. These molecules inhi-
bit metalloproteinases such as ADAM17, which are more
active in older populations and shed key receptors from
the MK surface to compromise platelet response to injury
[68,69]. Yet despite these improvements, the platelet yield
remains penury. Schlinker et al. [70] proposed a device
that could separate platelets from immature MKs, with
the latter then recycled in maturation medium to increase
their ploidy and platelet yield. Another consideration has
the MKs, not platelets, infused and shed platelets in the
blood stream resulting in in vivo generation [71].
Recapitulating the microenvironment
The potential of immortal MKs may be enhanced with
better recapitulation of the natural microenvironment in
which platelets are shed. One very simple adjustment is
switching the culture from two dimensions to three
dimensions, which has been reported to increase the num-
ber of progenitors [72]. Furthermore, three dimensions
make for more surface area, which could permit more
proplatelets to engage with the endothelial wall and there-
fore enhance the number of platelets acquired. Sullenbar-
ger et al. [73] prepared a 3D perfusion bioreactor using
scaffolds made of polyester fabric or hydrogel. They
showed that coating the scaffold with TPO or fibronectin
increased the number of platelets. The platelets, however,
were heterogeneous, with a number showing abnormal
shape and size. Building on this system, Pallotta et al.
[74] designed a bioreactor that included both the osteo-







CD34 + cells Platelets
ESCs and iPSs
Fig. 1. Ex vivo platelet generation has two major obstacles: the
expansion of CD34+ cells into megakaryocytes (MKs) and the shed-
ding of platelets from MKs. Prior to embryonic stem cells (ESCs)
and induced pluripotent stem cells (iPSCs), hematopoietic stem cells
(HSCs) were the only source of CD34+ cells. However, their expan-
sion remains too low for clinical use. Regulating the activation of
three transgenes, c-MYC, BMI-1, and BCL-XL, in iPSCs has led to
the creation of immortalized MKs. These cells can be cryopreserved
and have unlimited replication potential, which offers a solution to
the first obstacle.
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migrate by coating silk microtubes with the appropriate
extracellular matrix proteins and growth factors. An
important advantage of this system was the incorporation
of fluorescence imaging to observe MK migration and
platelet shedding live. The number of platelets per MK
was 200, which is within a magnitude of blood, but only
7% of MKs extended proplatelets toward the pseudo-
endothelial wall, suggesting ways that bias the proplat-
elets to the surface would be advantageous.
The osteoblast niche is a relatively hypoxic environ-
ment, a condition that is thought to preserve the pluripo-
tent state and regulate hematopoiesis [75,76]. Therefore,
bioreactors that are slightly hypoxic could help expand
CD34+ cells. Switching the microenvironment from 5%
oxygen at early-stage culturing to 20% at late stage was
shown to promote residence in the osteoblast niche and
platelet generation [77]. One theory for the stability is
that hypoxia causes less expression of vascular cell adhe-
sion molecule 1 and thus denies transition to the perivas-
cular niche [78]. The osteoblast niche can also be
stabilized using certain alkenes that enhance the expan-
sion of CD34+ cells [79].
Shear stress is an important factor in platelet number.
Thon et al. [80] have built a microfluidic bioreactor that
along with considering bone marrow stiffness, the extra-
cellular matrix composition, and other factors also incor-
porates shear stress. They found that the inclusion of
shear stress resulted in much faster rates of MK activa-
tion, as proplatelets began emerging within seconds of
trapping compared with the several hours seen in static
conditions and grew at much faster rates, reaching veloci-
ties that were comparable with those observed in living
mice. The shear stress in their system was generated by
parallel flows running around the scaffolds. Nakagawa
et al. [81] found, however, that a confluent system may be
more effective, as they reported that flow intersecting at
60° achieves a 3.6-fold increase from a single-flow system.
The reasons for this angle are unclear, but incorporating
such a feature into future bioreactors should not be a
major challenge.
The impact of flow may be further amplified by extra-
cellular matrix proteins. Results from a mouse model sug-
gest that vWF enhances the evisceration of proplatelets
by blood flow [33]. Additionally, shear stress increases the
expression of RUNX1 in CD41a+ cells, indicating that
biomechanical forces can promote hematopoietic develop-
ment [82]. Consistently, another biomechanical property,
elasticity, was found to enhance the expansion of CD34+
cells [83].
Conclusions
A major challenge in the field of platelet research is gen-
erating the massive number of platelets needed for viable
patient care. Despite advances in ex vivo techniques, there
are still ways to go before seeing ex vivo platelets reach
the clinic. Key advances in the field, however, are bring-
ing this goal closer to reality. Bioreactors that better reca-
pitulate the MK environment by including key
extracellular matrix proteins and the effects of shear stress
have shown that platelet totals can be increased by sev-
eral factors. Perhaps more important is the invention of
immortalized MKs. These cells can be maintained for sev-
eral months, which reduces the storage concern of plate-
lets. Introducing immortalized MKs into advanced
bioreactors may contribute to the significant leap needed
in ex vivo platelet generation.
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